This inventor holds 1 USPTO granted patent. Top assignee: Neophore Limited. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Jon Roffey: Innovator in Cancer Treatment
Introduction
Jon Roffey is a notable inventor based in London, GB. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on targeting specific proteins involved in the DNA Mismatch Repair process, which is crucial for maintaining genomic stability.
Latest Patents
Jon Roffey holds a patent for "Inhibitors of MLH1 and/or PMS2 for cancer treatment." This invention relates to compounds of Formula (I) that specifically target the MLH1 and/or PMS2 proteins. These proteins play a vital role in the DNA Mismatch Repair (MMR) process, and the compounds developed by Roffey aim to enhance cancer treatment efficacy.
Career Highlights
Throughout his career, Jon Roffey has been associated with Neophore Limited, a company dedicated to advancing cancer therapies. His work has been instrumental in developing novel approaches to cancer treatment, showcasing his commitment to improving patient outcomes.
Collaborations
Jon Roffey has collaborated with esteemed colleagues such as Julian Blagg and Paul Winship. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the pursuit of effective cancer therapies.
Conclusion
Jon Roffey's contributions to cancer treatment through his patent and collaborative efforts highlight his role as a significant innovator in the field. His work continues to pave the way for advancements in cancer therapies, ultimately benefiting patients worldwide.